Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Contracts + Grants

    AbCellera to Lead Development of Rapid Response Platform Against Pandemic Threats

    By Global Biodefense StaffMarch 14, 2018
    Biodefense News - Industry Updates
    Share
    Facebook LinkedIn Reddit Email

    AbCellera Biologics Inc. this week announced that it was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to develop rapid countermeasures against viral outbreaks.

    Under DARPA’s Pandemic Prevention Platform (P3) program, AbCellera will receive up to USD $30 million in funding to establish an end-to-end platform for rapid pandemic response, and will lead an internationally recognized team of experts in virology, antibody discovery, and gene therapy.

    The P3 program seeks to develop a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of a viral pathogen. To achieve this ambitious goal, AbCellera and its partners will develop and integrate innovative technologies for viral culture and production, rapid human antibody discovery, protein engineering, and delivery of nucleic acid-encoded antibodies as prophylactic protection against viral infection.

    AbCellera’s platform development and testing will include the discovery of thousands of human antibodies against a wide array of influenza strains and validation using a variety of other high-priority viral pathogens.

    Read more: Stopping Pandemic X: DARPA Names Researchers Working to Halt Outbreaks

    “Through the P3 program, DARPA has set a bold vision to establish effective response capabilities for viral threats. The recent Ebola and Zika pandemics have made it clear that we are not equipped to deal with viral pandemics,” noted Carl Hansen, founding CEO of AbCellera. “The severity of seasonal flu this year is a sobering reminder that viral outbreaks present a serious risk to public health for which we must be better prepared.”

    AbCellera is a privately held company based in Vancouver, BC. AbCellera’s single-cell platform integrates end-to-end capabilities for therapeutic antibody discovery through a combination of technologies including proprietary immunizations, microfluidics, high-throughput imaging, genomics, computation, and laboratory automation.

    Sources: AbCellera Biologics Inc., DARPA. Edited for context and format by Global Biodefense.

    Antivirals Avian Influenza Awards DARPA Emerging Threats Influenza Pandemic Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleWhat We Know About the Soviet-Designed Nerve Agent Novichok
    Next Article Slowing Biological Time: DARPA Hosting Webinar for Biostasis BAA

    Related Stories

    Valley Fever: An Invisible Killer Expands Its Range in the American West

    November 17, 2023

    Inflammatix Completes Development for Acute Infection and Sepsis Test System

    November 15, 2023

    Virginia Tech Lab Selected for National Partnership to Fight Emerging Diseases

    November 14, 2023

    NanoViricides’ Phase 1 Broad-Spectrum Antiviral Highly Effective for Mpox and Smallpox

    November 14, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.